Sign Out
Postmenopausal Osteoporosis: Treatment of osteoporosis in postmenopausal women at increased risk of fractures. In postmenopausal women with osteoporosis, Denosumab increases bone mineral density (BMD) and reduces the incidence of hip, vertebral and non-vertebral fractures.
Bone Loss in Patients Undergoing Hormone Ablation for Cancer: Treatment of bone loss in patients undergoing hormone ablation for prostate or breast cancer at increased risk of fractures (see Pharmacology: Pharmacodynamics under Actions). In patients with prostate cancer, denosumab reduces the incidence of vertebral fractures.
Male Osteoporosis: Treatment of osteoporosis in men at the increased risk of fractures.
Glucocorticoid-Induced Osteoporosis: Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see Pharmacology: Pharmacodynamics under Actions).
Continue with Google